ŠANGHAJ, KITAJSKA in CAMBRIDGE, MASSACHUSETTS, ZDA, 27. oktober 2022 – JW Therapeutics (HKEX: 2126), neodvisno in inovativno biotehnološko podjetje, ki se osredotoča na razvoj, proizvodnjo in trženje izdelkov celične imunoterapije, in 2seventy Biografija (NASDAQ: TSVT), vodilno podjetje za imunoonkološko celično terapijo, je danes objavilo strateško zavezništvo za vzpostavitev translacijske in klinične platforme za razvoj celične terapije, namenjene hitrejšemu raziskovanju Imunoterapija na osnovi T celic izdelke v celinski Kitajski, Hongkongu (Kitajska) in Macau (Kitajska).
The initial focus of the collaboration is 2seventy’s MAGE-A4 TCR program in solid tumors, which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. The program is designed to develop Terapije s T-celičnimi receptorji (TCR). za zdravljenje MAGE-A4 pozitivnih solidnih tumorjev.
Morda boste radi prebrali: CAR T-Cell terapija na Kitajskem
“We are delighted to work with 2Seventy bio to jointly develop the MAGE-A4 TCR program and potentially other assets in China,” said Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics. “2Seventy is a top-tier cell therapy company with advanced technologies and a highly experienced team. This alliance will further leverage our world-class integrated capabilities, including translational research and clinical development, and we look forward to accelerating the development of more cell immunotherapy products with breakthrough therapeutic value to serve more patients with cancer in China and potentially worldwide.”
“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn, and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2Seventy bio. “JW Therapeutics possesses extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China, as well as the clinical development pathways. The opportunity to bring together our distinctive areas of experience to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”
Morda boste radi prebrali: Cena CAR T-celične terapije na Kitajskem
V skladu s pogoji pogodbe bo 2seventy JW Therapeutics podelil licenco za celično terapijo MAGE-A4 na celinski Kitajski, v Hong Kongu (Kitajska) in Macau (Kitajska). JW Therapeutics bo odgovoren za razvoj, proizvodnjo in komercializacijo na Kitajskem. 2seventy je upravičen do prejemanja mejnikov in licenčnin za prihodke od izdelkov na Kitajskem. Poleg tega lahko 2seventy izkoristi zgodnje klinične podatke, ustvarjene v okviru sodelovanja, za podporo razvoju na drugih območjih. Zaključek transakcije bo odvisen od odobritve delničarjev JW Therapeutics in drugih običajnih zaključnih pogojev.
O programu MAGE-A4
MAGE-A4 je član družine MAGE antigenov raka testisov, izraženih v številnih tipih solidnih tumorjev. Naš program uporablja zelo močan TCR, odkrit v našem sodelovanju z MediGene
ki prepozna HLA-predstavljene peptide MAGE-A4 in dodatno poveča moč teh preusmerjenih celic T z našo tehnologijo "flip" receptorja CTBR12 TGF-beta, ki pretvori imunosupresivne učinke TGF-beta v aktivacijski signal za celice T . Regeneron in 2seventy bio skupaj razvijata program v okviru sodelovanja, sklenjenega leta 2018.
Morda boste radi prebrali: CAR T-celična terapija za multipli mielom na Kitajskem
O JW Therapeutics
JW Therapeutics (HKEX: 2126) je neodvisno in inovativno biotehnološko podjetje, ki se osredotoča na razvoj, proizvodnjo in komercializacijo izdelkov za celično imunoterapijo ter je zavezano postati vodilni na področju inovacij na področju celične imunoterapije. Podjetje JW Therapeutics, ustanovljeno leta 2016, je zgradilo platformo svetovnega razreda za razvoj izdelkov v celični imunoterapiji, pa tudi nabor izdelkov, ki pokriva tako hematološke malignome kot solidne tumorje. JW Therapeutics se zavzema za zagotavljanje prebojnih in kakovostnih izdelkov za celično imunoterapijo in upanje na ozdravitev pacientom na Kitajskem in po svetu ter vodi zdrav in standardiziran razvoj Kitajska celična imunoterapija industriji.
Približno 2 biografij
Naše ime, 2seventy bio, odraža, zakaj počnemo to, kar počnemo – ČAS. Rak krati čas in naš cilj je delati z največjo hitrostjo prevajanja človeške misli v dejanja – 270 milj na uro – da bi ljudem, ki jim služimo, dali več časa. Gradimo vodilno podjetje za imunoonkološko celično terapijo, osredotočeno na odkrivanje in razvoj novih terapij, ki resnično motijo krajino zdravljenja raka.
Z globokim razumevanjem imunskega odziva človeškega telesa na tumorske celice in kako celične terapije prevesti v prakso, uporabljamo to znanje za zagotavljanje celičnih terapij naslednje generacije, ki se osredotočajo na širok spekter hematoloških malignomov, vključno s prvimi, ki jih je odobrila FDA CAR T celična terapija za multipli mielom, kot tudi solidni tumorji. Naše raziskave in razvoj so osredotočeni na zagotavljanje terapij, ki so zasnovane s ciljem »razmišljanja« pametnejšega in hitrejšega od bolezni. Pomembno je, da ostajamo osredotočeni na doseganje teh ciljev, tako da ostajamo pristni in verodostojni svojemu »zakaj« ter dajemo svoje ljudi in kulturo vsak dan na prvo mesto.
Izjave JW Therapeutics o prihodnosti
The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEX) reports filed by the company. Unless otherwise noted, the company is providing this information as of the date it publicized, and expressly disclaims any duty to update the information contained in the issues and relevant information, or provide any explanation.
Morda boste radi prebrali: FUCASO za zdravljenje multiplega mieloma
Opozorilo v zvezi z izjavami o prihodnosti 2seventy bio
Ta objava vsebuje "v prihodnost usmerjene izjave" v smislu Zakona o reformi sodnih sporov o zasebnih vrednostnih papirjih iz leta 1995. Te izjave vključujejo, vendar niso omejene na: izjave o naših načrtih, strategijah, časovnicah in pričakovanjih v zvezi z razvojem, proizvodnjo ali prodajo naših kandidatov za izdelke, vključno z rezultati in pričakovanim časom tekočih in načrtovanih kliničnih preskušanj za naše kandidate za izdelke na Kitajskem in hitrostjo, s katero lahko te kandidate pripeljemo do kliničnih preskušanj; statements about the efficacy and perceived therapeutic benefits of our product candidates and the potential indications, market opportunities and demand therefor; statements about the strategic plans for 2seventy bio and potential corporate development opportunities; statements regarding the company’s financial condition, and other future financial results; and statements about our ability to execute our strategic priorities.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation; the risk that our plans with respect to the preclinical and clinical development and regulatory approval of our product candidates may not be successfully achieved on the planned timeline, or at all.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, as supplemented and/or modified by our most recent Quarterly Report on Form 10-Q and any other filings that we have made or will make with the Securities and Exchange Commission in the future.
All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.
